American Assets Investment Management LLC maintained its position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,000 shares of the medical instruments supplier’s stock at the end of the second quarter. American Assets Investment Management LLC’s holdings in Becton, Dickinson and were worth $976,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. PHH Investments Ltd. lifted its stake in shares of Becton, Dickinson and by 29.7% in the second quarter. PHH Investments Ltd. now owns 8,746 shares of the medical instruments supplier’s stock worth $1,706,000 after acquiring an additional 2,005 shares during the period. Legal & General Group Plc lifted its stake in shares of Becton, Dickinson and by 7.6% in the second quarter. Legal & General Group Plc now owns 1,224,415 shares of the medical instruments supplier’s stock worth $238,903,000 after acquiring an additional 85,987 shares during the period. Arcadia Investment Management Corp MI lifted its stake in shares of Becton, Dickinson and by 1.9% in the second quarter. Arcadia Investment Management Corp MI now owns 31,065 shares of the medical instruments supplier’s stock worth $6,061,000 after acquiring an additional 586 shares during the period. State of Wisconsin Investment Board lifted its stake in shares of Becton, Dickinson and by 21.5% in the second quarter. State of Wisconsin Investment Board now owns 203,650 shares of the medical instruments supplier’s stock worth $39,734,000 after acquiring an additional 35,996 shares during the period. Finally, Dowling & Yahnke LLC lifted its stake in shares of Becton, Dickinson and by 2.1% in the second quarter. Dowling & Yahnke LLC now owns 7,891 shares of the medical instruments supplier’s stock worth $1,540,000 after acquiring an additional 165 shares during the period. 87.43% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/17/american-assets-investment-management-llc-maintains-holdings-in-becton-dickinson-and-company-bdx.html.

In other news, insider Stephen Sichak sold 11,787 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the transaction, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is currently owned by company insiders.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 195.34 on Friday. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The stock’s 50 day moving average price is $199.43 and its 200 day moving average price is $191.33. The company has a market cap of $44.45 billion, a P/E ratio of 56.57 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.35 EPS. On average, analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is presently 83.43%.

A number of equities analysts recently commented on the company. Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, July 17th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $196.93.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.